Switch theme
Sign up to access all valuation multiples
Granules India Ltd is an India-based pharmaceutical company. The company manufactures active pharmaceutical ingredients, pharmaceutical formulation intermediates, and finished dosages. It has one segment Pharmaceutical products including ingredients and intermediaries. Its primary geographic markets are North America, Latin America, Europe, India, and the Rest of the World. The company generates a majority of its revenue from its business outside India.
1991
4.1K+
LTM Revenue $538M
LTM EBITDA $114M
$1.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Granules India has a last 12-month revenue (LTM) of $538M and a last 12-month EBITDA of $114M.
In the most recent fiscal year, Granules India achieved revenue of $522M and an EBITDA of $116M.
Granules India expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Granules India valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $538M | XXX | $522M | XXX | XXX | XXX |
| Gross Profit | $330M | XXX | $320M | XXX | XXX | XXX |
| Gross Margin | 61% | XXX | 61% | XXX | XXX | XXX |
| EBITDA | $114M | XXX | $116M | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 22% | XXX | XXX | XXX |
| EBIT | $87.3M | XXX | $84.3M | XXX | XXX | XXX |
| EBIT Margin | 16% | XXX | 16% | XXX | XXX | XXX |
| Net Profit | $57.8M | XXX | $58.7M | XXX | XXX | XXX |
| Net Margin | 11% | XXX | 11% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $96.0M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Granules India's stock price is INR 531 (or $6).
Granules India has current market cap of INR 129B (or $1.5B), and EV of INR 137B (or $1.6B).
See Granules India trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.6B | $1.5B | XXX | XXX | XXX | XXX | $0.24 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Granules India has market cap of $1.5B and EV of $1.6B.
Granules India's trades at 3.1x EV/Revenue multiple, and 14.5x EV/EBITDA.
Equity research analysts estimate Granules India's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Granules India has a P/E ratio of 26.1x.
See valuation multiples for Granules India and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.5B | XXX | $1.5B | XXX | XXX | XXX |
| EV (current) | $1.6B | XXX | $1.6B | XXX | XXX | XXX |
| EV/Revenue | 3.0x | XXX | 3.1x | XXX | XXX | XXX |
| EV/EBITDA | 14.1x | XXX | 14.5x | XXX | XXX | XXX |
| EV/EBIT | 18.4x | XXX | 19.5x | XXX | XXX | XXX |
| EV/Gross Profit | 4.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | 26.1x | XXX | 27.0x | XXX | XXX | XXX |
| EV/FCF | 71.0x | XXX | 58.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialGranules India's last 12 month revenue growth is 15%
Granules India's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Granules India's rule of 40 is 36% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Granules India's rule of X is 58% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Granules India and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 15% | XXX | 13% | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 21% | XXX | XXX | XXX |
| EBITDA Growth | 19% | XXX | 17% | XXX | XXX | XXX |
| Rule of 40 | 36% | XXX | 36% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 58% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 45% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Granules India acquired XXX companies to date.
Last acquisition by Granules India was XXXXXXXX, XXXXX XXXXX XXXXXX . Granules India acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Granules India founded? | Granules India was founded in 1991. |
| Where is Granules India headquartered? | Granules India is headquartered in India. |
| How many employees does Granules India have? | As of today, Granules India has 4.1K+ employees. |
| Who is the CEO of Granules India? | Granules India's CEO is Dr. Kandiraju Venkata Sitaramrao. |
| Is Granules India publicy listed? | Yes, Granules India is a public company listed on BOM. |
| What is the stock symbol of Granules India? | Granules India trades under 532482 ticker. |
| When did Granules India go public? | Granules India went public in 2002. |
| Who are competitors of Granules India? | Similar companies to Granules India include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Granules India? | Granules India's current market cap is $1.5B |
| What is the current revenue of Granules India? | Granules India's last 12 months revenue is $538M. |
| What is the current revenue growth of Granules India? | Granules India revenue growth (NTM/LTM) is 15%. |
| What is the current EV/Revenue multiple of Granules India? | Current revenue multiple of Granules India is 3.0x. |
| Is Granules India profitable? | Yes, Granules India is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Granules India? | Granules India's last 12 months EBITDA is $114M. |
| What is Granules India's EBITDA margin? | Granules India's last 12 months EBITDA margin is 21%. |
| What is the current EV/EBITDA multiple of Granules India? | Current EBITDA multiple of Granules India is 14.1x. |
| What is the current FCF of Granules India? | Granules India's last 12 months FCF is $22.7M. |
| What is Granules India's FCF margin? | Granules India's last 12 months FCF margin is 4%. |
| What is the current EV/FCF multiple of Granules India? | Current FCF multiple of Granules India is 71.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
